WSL
FTH

Western Standard LLC’s Faeth Therapeutics FTH Stock Holding History

Western Standard LLC’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,306
Closed -$68.7K – 33
2022
Q4 		$68.7K Buy
+2,306
New +$67.8K 0.06% 27

Other funds holding FTH

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Western Standard LLC's FTH Position: Q1 2023 in Review

Western Standard LLC sold out of Faeth Therapeutics (FTH) in Q1 2023, closing a stake of 2,306 shares — an estimated $68.7K sold.

Western Standard LLC first reported a position in FTH in Q4 2022 and held it in 1 quarter. The position peaked at $68.7K in Q4 2022. 26 funds tracked by Wall St. Rank hold FTH as of Q1 2023.

  • Western Standard LLC reported no remaining Faeth Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Western Standard LLC sold 2,306 Faeth Therapeutics shares in Q1 2023, an estimated $68.7K.
  • Western Standard LLC first reported a position in Faeth Therapeutics in Q4 2022 and held it in 1 quarter.
  • Western Standard LLC's Faeth Therapeutics position peaked at $68.7K in Q4 2022.
  • 26 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2023.

Based on Western Standard LLC's 13F filing for Q1 2023, filed 15 May 2023.